Skip Navigation

William Barry, PhD



Researcher

  • Nancy and Morris John Lurie Investigator

Contact Information

  • Office Phone Number617-632-5134
  • Fax617-632-2444

Bio

Dr Barry received a PhD in Biostatistics from the University of North Carolina in Chapel Hill in 2006, and from 2007 to 2012 served as an Assistant Professor in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine. Starting in 2009 he became the Director of the Bioinformatics Shared Resource for the Duke Cancer Institute.  Dr Barry has also participation in the NCI's Clinical Trials Cooperative Group Program since 2007 as a faculty member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B).

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
CLSB 11005
Boston MA, 02215
Get Directions

Research

Statistical Methods in Cancer Research

Applied research interests are in clinical and translational research in cancer, undertaken through collaborations at Duke and Dana-Farber Cancer Institutes, and through participation in the NCI's Clinical Trials Cooperative Group Program since 2007 as a faculty member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B). This includes biostatistical lead in multiple Phase II and III clinical trials and retrospective/prospective validations of tumor biomarkers.

Methodologic research interests are various topics on the use of high-throughput technologies in clinical and translational research, including resampling-based methods for inference and multiple comparisons; Bayesian methods for discrimination; and the use of adaptive designs for Phase II trials in cancer with integral biomarkers.

This work has appeared in over 50 co-authored peer-reviewed publications, and serves as the basis for invited lectures and workshops given to the American Society for Clinical Oncology (ASCO), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR) and the European Organization for Research and Treatment of Cancer (EORTC).

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):173-182.
View in: PubMed

Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Jan 13.
View in: PubMed

Magbanua MJM, Rugo HS, Wolfe DM, Hauranieh L, Roy R, Pendyala P, Sosa E, Scott JH, Lee JS, Pitcher BN, Hyslop TM, Barry WT, Isakoff SJ, Dickler MN, Van't Veer LJ, Park JW. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time. Clin Cancer Res. 2018 Jan 08.
View in: PubMed

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 Jan 03; JCO2017760033.
View in: PubMed

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017; 3:37.
View in: PubMed

Sagara Y, Freedman RA, Wong SM, Aydogan F, Nguyen A, Barry WT, Golshan M. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. Breast Cancer Res Treat. 2017 Nov; 166(2):583-592.
View in: PubMed

Regan MM, Barry WT. Trial designs and results supporting treatment de-escalation and escalation. Breast. 2017 Aug; 34 Suppl 1:S10-S12.
View in: PubMed

Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS. Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. Am J Surg. 2017 Oct; 214(4):687-694.
View in: PubMed

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 Sep; 19(5):1411-1423.
View in: PubMed

Hill KE, Kelly AD, Kuijjer ML, Barry W, Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A, Goldsmith J, Gebhardt MC, Arredouani MS, Cote G, Hornicek F, Choy E, Duan Z, Quackenbush J, Haibe-Kains B, Spentzos D. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 May 15; 10(1):107.
View in: PubMed

Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat. 2017 Jul; 164(1):107-117.
View in: PubMed

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
View in: PubMed

Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. J Natl Compr Canc Netw. 2017 03; 15(3):316-324.
View in: PubMed

Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg. 2017 03; 265(3):581-589.
View in: PubMed

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist. 2017 Apr; 22(4):386-393.
View in: PubMed

Ventz S, Barry WT, Parmigiani G, Trippa L. Bayesian response-adaptive designs for basket trials. Biometrics. 2017 Sep; 73(3):905-915.
View in: PubMed

Kelley MJ, Jha G, Shoemaker D, Herndon JE, Gu L, Barry WT, Crawford J, Ready N. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Invest. 2017 Jan 02; 35(1):32-35.
View in: PubMed

Masko EM, Alfaqih MA, Solomon KR, Barry WT, Newgard CB, Muehlbauer MJ, Valilis NA, Phillips TE, Poulton SH, Freedland AR, Sun S, Dambal SK, Sanders SE, Macias E, Freeman MR, Dewhirst MW, Pizzo SV, Freedland SJ. Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Prostate. 2017 Apr; 77(5):446-457.
View in: PubMed

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2017 01; 22(1):25-32.
View in: PubMed

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
View in: PubMed

Sagara Y, Freedman RA, Mallory MA, Wong SM, Barry WT, Golshan M. Reply to K. Lin et al. J Clin Oncol. 2016 Oct 01; 34(28):3485-6.
View in: PubMed

Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res. 2016 Dec 15; 22(24):6039-6050.
View in: PubMed

Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96.
View in: PubMed

Kennedy S, Caldwell M, Bydlon T, Mulvey C, Mueller J, Wilke L, Barry W, Ramanujam N, Geradts J. Correlation of breast tissue histology and optical signatures to improve margin assessment techniques. J Biomed Opt. 2016 Jun 01; 21(6):66014.
View in: PubMed

Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5755-5764.
View in: PubMed

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 Aug 01; 34(22):2602-9.
View in: PubMed

Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Oncologist. 2016 06; 21(6):666-70.
View in: PubMed

Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg. 2016 Mar 08.
View in: PubMed

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Aug 01; 22(15):3764-73.
View in: PubMed

Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, Lis RL, Cotter MB, Loda M, Barry WT, Polyak K, Tamimi RM. The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. Cancer Res. 2016 04 01; 76(7):1926-34.
View in: PubMed

Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. J Clin Oncol. 2016 Apr 10; 34(11):1190-6.
View in: PubMed

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016 Jan 21; 529(7586):413-417.
View in: PubMed

Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016; 2.
View in: PubMed

Ligibel JA, Winer E, Hudis CA, Barry WT. Response. J Natl Cancer Inst. 2016 Jan; 108(1).
View in: PubMed

Ligibel JA, Winer E, Hudis CA, Barry WT. Response. J Natl Cancer Inst. 2015 Jan; 108(1).
View in: PubMed

Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discov. 2016 Jan; 6(1):45-58.
View in: PubMed

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20; 34(6):542-9.
View in: PubMed

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14325-30.
View in: PubMed

Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer. 2015 Dec 15; 121(24):4333-40.
View in: PubMed

Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, Golshan M. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study. JAMA Surg. 2015 Aug; 150(8):739-45.
View in: PubMed

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
View in: PubMed

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14.
View in: PubMed

Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9).
View in: PubMed

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9.
View in: PubMed

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707.
View in: PubMed

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
View in: PubMed

Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol. 2015 Dec; 22(13):4280-6.
View in: PubMed

Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JT, Hwang ES. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. Int J Radiat Oncol Biol Phys. 2015 Jul 15; 92(4):846-55.
View in: PubMed

Greaney ML, Sprunck-Harrild K, Ruddy KJ, Ligibel J, Barry WT, Baker E, Meyer M, Emmons KM, Partridge AH. Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. BMC Public Health. 2015 Jan 31; 15:37.
View in: PubMed

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
View in: PubMed

Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. J Biopharm Stat. 2015; 25(1):66-88.
View in: PubMed

Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.
View in: PubMed

Meltzer EB, Barry WT, Yang IV, Brown KK, Schwarz MI, Patel H, Ashley A, Noble PW, Schwartz DA, Steele MP. Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. BMC Genomics. 2014 Oct 16; 15:902.
View in: PubMed

Carey LA, Barry W. Making sense of dual HER2-targeting in early breast cancer? J Natl Cancer Inst. 2014 Sep; 106(9).
View in: PubMed

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in: PubMed

Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer. 2014 Oct 14; 111(8):1532-41.
View in: PubMed

Barry WT, Birrer MJ, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA5500.
View in: PubMed

Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. ß-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol. 2014 Aug; 134(2):426-7.
View in: PubMed

Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol. 2014 Aug 01; 32(22):2318-27.
View in: PubMed

Mills R, Powell J, Barry W, Haga SB. Information-seeking and sharing behavior following genomic testing for diabetes risk. J Genet Couns. 2015 Feb; 24(1):58-66.
View in: PubMed

Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv. 2014 Dec; 8(4):627-37.
View in: PubMed

Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6.
View in: PubMed

Stevenson M, Christensen J, Shoemaker D, Foster T, Barry WT, Tong BC, Wahidi M, Shofer S, Datto M, Ginsburg G, Crawford J, D'Amico T, Ready N. Tumor acquisition for biomarker research in lung cancer. Cancer Invest. 2014 Jul; 32(6):291-8.
View in: PubMed

Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501.
View in: PubMed

Haga SB, Barry WT, Mills R, Svetkey L, Suchindran S, Willard HF, Ginsburg GS. Impact of delivery models on understanding genomic risk for type 2 diabetes. Public Health Genomics. 2014; 17(2):95-104.
View in: PubMed

Mills R, Barry W, Haga SB. Public trust in genomic risk assessment for type 2 diabetes mellitus. J Genet Couns. 2014 Jun; 23(3):401-8.
View in: PubMed

Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
View in: PubMed

Brown JQ, Bydlon TM, Kennedy SA, Caldwell ML, Gallagher JE, Junker M, Wilke LG, Barry WT, Geradts J, Ramanujam N. Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins. PLoS One. 2013; 8(7):e69906.
View in: PubMed

Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turkington TG, Dewhirst MW. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 2013 Sep; 6(9):925-37.
View in: PubMed

Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. J Geriatr Oncol. 2013 Oct; 4(4):353-61.
View in: PubMed

Zhou YH, Barry WT, Wright FA. Empirical pathway analysis, without permutation. Biostatistics. 2013 Jul; 14(3):573-85.
View in: PubMed

Haga SB, Barry WT, Mills R, Ginsburg GS, Svetkey L, Sullivan J, Willard HF. Public knowledge of and attitudes toward genetics and genetic testing. Genet Test Mol Biomarkers. 2013 Apr; 17(4):327-35.
View in: PubMed

Bydlon TM, Barry WT, Kennedy SA, Brown JQ, Gallagher JE, Wilke LG, Geradts J, Ramanujam N. Advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast. PLoS One. 2012; 7(12):e51418.
View in: PubMed

Liao S, Desouki MM, Gaile DP, Shepherd L, Nowak NJ, Conroy J, Barry WT, Geradts J. Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer. 2012 Dec; 51(12):1067-78.
View in: PubMed

Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res. 2012 Oct 01; 18(19):5489-98.
View in: PubMed

Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA1002.
View in: PubMed

Mandelblatt JS, Faul LA, Luta G, Makgoeng SB, Isaacs C, Taylor K, Sheppard VB, Tallarico M, Barry WT, Cohen HJ. Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. J Clin Oncol. 2012 Jul 20; 30(21):2609-14.
View in: PubMed

Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology. 2012 Jul; 80(1):162-7.
View in: PubMed

Stevenson M, Mostertz W, Acharya CR, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res. 2012 Mar 15; 18(6):1818.
View in: PubMed

Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther. 2012 Jul; 11(7):1500-1509.
View in: PubMed

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587. JAMA. 2012 Feb 01; 307(5):453.
View in: PubMed

Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P, Nevins JR. SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics. 2011 Nov 14; 12:443.
View in: PubMed

Owzar K, Barry WT, Jung SH. Statistical considerations for analysis of microarray experiments. Clin Transl Sci. 2011 Dec; 4(6):466-77.
View in: PubMed

Meltzer EB, Barry WT, D'Amico TA, Davis RD, Lin SS, Onaitis MW, Morrison LD, Sporn TA, Steele MP, Noble PW. Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. BMC Med Genomics. 2011 Oct 05; 4:70.
View in: PubMed

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2011 Oct 18; 108(42):17569.
View in: PubMed

Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR. A methodology for utilization of predictive genomic signatures in FFPE samples. BMC Med Genomics. 2011 Jul 11; 4:58.
View in: PubMed

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat. 2012 Apr; 132(2):487-98.
View in: PubMed

Kuderer NM, Culakova E, Huang M, Poniewierski MS, Ginsburg GS, Barry WT, Marcom PK, Ready N, Abernethy AP, Lyman GH. Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):3082.
View in: PubMed

Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, Schmieder L, Ansari R, Tew WP, Weckstein D, Kirshner J, Togawa K, Hansen K, Katheria V, Stone R, Galinsky I, Postiglione J, Cohen HJ. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011 Apr 01; 29(10):1290-6.
View in: PubMed

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):476-82.
View in: PubMed

Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecol Oncol. 2011 Apr; 121(1):187-92.
View in: PubMed

Kennedy S, Geradts J, Bydlon T, Brown JQ, Gallagher J, Junker M, Barry W, Ramanujam N, Wilke L. Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast. Breast Cancer Res. 2010; 12(6):R91.
View in: PubMed

Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010 Nov; 28(9):969-77.
View in: PubMed

Gatti DM, Barry WT, Nobel AB, Rusyn I, Wright FA. Heading down the wrong pathway: on the influence of correlation within gene sets. BMC Genomics. 2010 Oct 18; 11:574.
View in: PubMed

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010 Oct 06; 102(19):1496-512.
View in: PubMed

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer. 2010 Jun 15; 126(12):2893-903.
View in: PubMed

Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol. 2010 Jul 01; 28(19):3146-53.
View in: PubMed

Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010 May 01; 28(13):2198-206.
View in: PubMed

Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010 Apr 13; 107(15):6994-9.
View in: PubMed

Brown JQ, Bydlon TM, Richards LM, Yu B, Kennedy SA, Geradts J, Wilke LG, Junker M, Gallagher J, Barry W, Ramanujam N. Optical assessment of tumor resection margins in the breast. IEEE J Sel Top Quantum Electron. 2010 Mar 01; 16(3):530-544.
View in: PubMed

Shea PR, Virtaneva K, Kupko JJ, Porcella SF, Barry WT, Wright FA, Kobayashi SD, Carmody A, Ireland RM, Sturdevant DE, Ricklefs SM, Babar I, Johnson CA, Graham MR, Gardner DJ, Bailey JR, Parnell MJ, Deleo FR, Musser JM. Interactome analysis of longitudinal pharyngeal infection of cynomolgus macaques by group A Streptococcus. Proc Natl Acad Sci U S A. 2010 Mar 09; 107(10):4693-8.
View in: PubMed

Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, Morse MA, Lyerly HK, Clay TM. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res. 2010 Mar 01; 16(5):1466-77.
View in: PubMed

Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, Barry W, Crawford J, Nevins J, Potti A. Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA. 2010 Feb 10; 303(6):535-43.
View in: PubMed

Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res. 2009 Dec 15; 15(24):7553-61.
View in: PubMed

Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res. 2009 Nov 15; 15(22):6947-55.
View in: PubMed

Wilke LG, Brown JQ, Bydlon TM, Kennedy SA, Richards LM, Junker MK, Gallagher J, Barry WT, Geradts J, Ramanujam N. Rapid noninvasive optical imaging of tissue composition in breast tumor margins. Am J Surg. 2009 Oct; 198(4):566-74.
View in: PubMed

Vishwanath K, Yuan H, Barry WT, Dewhirst MW, Ramanujam N. Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors. Neoplasia. 2009 Sep; 11(9):889-900.
View in: PubMed

Bottone FG, Barry WT. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Curr Med Res Opin. 2009 Jun; 25(6):1535-50.
View in: PubMed

Tuchman SA, Chng W, Anguiano A, Barry WT, Zhan F, Gasparetto C, Fonseca R, Shaughnessy JD, Potti A. The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation. J Clin Oncol. 2009 May 20; 27(15_suppl):8521.
View in: PubMed

Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A. Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):11001.
View in: PubMed

Marcom PK, Datto MB, Barry WT, Geradts J, Foster TL, Dressman HK, Olson J, Potti A, Ginsburg G, Nevins JR. Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial. J Clin Oncol. 2009 May 20; 27(15_suppl):11057.
View in: PubMed

Mandelblatt J, Sheppard V, Hurria A, Kimmick G, Isaacs C, Taylor K, Luta G, Noone A, Kornblith A, Barry W. Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB #369901. J Clin Oncol. 2009 May 20; 27(15_suppl):9544.
View in: PubMed

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009 Apr 20; 27(12):2022-9.
View in: PubMed

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A. 2009 Mar 31; 106(13):5312-7.
View in: PubMed

Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):901-14.
View in: PubMed

Ramanujam N, Brown J, Bydlon TM, Kennedy SA, Richards LM, Junker MK, Gallagher J, Barry WT, Wilke LG, Geradts J. Quantitative spectral reflectance imaging device for intraoperative breast tumor margin assessment. Conf Proc IEEE Eng Med Biol Soc. 2009; 2009:6554-6.
View in: PubMed

Gatti DM, Sypa M, Rusyn I, Wright FA, Barry WT. SAFEGUI: resampling-based tests of categorical significance in gene expression data made easy. Bioinformatics. 2009 Feb 15; 25(4):541-2.
View in: PubMed

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19432-7.
View in: PubMed

Owzar K, Barry WT, Jung SH, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res. 2008 Oct 01; 14(19):5959-66.
View in: PubMed

Barry WT, Datto M, Geradts J, Foster T, Olson J, Marcom PK, Dressman HK, Nevins JR, Ginsburg G, Potti A. Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples. J Clin Oncol. 2008 May 20; 26(15_suppl):11068.
View in: PubMed

Mendiratta P, Tewari A, Guinney J, Porrello A, Barry WT, Febbo PG. A genomic strategy for targeting therapy in castration-Independent Prostate Cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5067.
View in: PubMed

Garst J, Datto M, Herndon JE, Barry WT, Shoemaker D, Bjurstrom A, Andrews C, Ginsburg G, Nevins JR, Potti A. A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):8108.
View in: PubMed

Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One. 2008 Apr 02; 3(4):e1908.
View in: PubMed

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008 Apr 02; 299(13):1574-87.
View in: PubMed

Wright FA, Huang H, Guan X, Gamiel K, Jeffries C, Barry WT, de Villena FP, Sullivan PF, Wilhelmsen KC, Zou F. Simulating association studies: a data-based resampling method for candidate regions or whole genome scans. Bioinformatics. 2007 Oct 01; 23(19):2581-8.
View in: PubMed

Graham MR, Virtaneva K, Porcella SF, Gardner DJ, Long RD, Welty DM, Barry WT, Johnson CA, Parkins LD, Wright FA, Musser JM. Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection. Am J Pathol. 2006 Sep; 169(3):927-42.
View in: PubMed

Graham MR, Virtaneva K, Porcella SF, Barry WT, Gowen BB, Johnson CR, Wright FA, Musser JM. Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am J Pathol. 2005 Feb; 166(2):455-65.
View in: PubMed

Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics. 2005 May 01; 21(9):1943-9.
View in: PubMed

Hester SD, Barry WT, Zou F, Wolf DC. Transcriptomic analysis of F344 rat nasal epithelium suggests that the lack of carcinogenic response to glutaraldehyde is due to its greater toxicity compared to formaldehyde. Toxicol Pathol. 2005; 33(4):415-24.
View in: PubMed

Hester SD, Benavides GB, Yoon L, Morgan KT, Zou F, Barry W, Wolf DC. Formaldehyde-induced gene expression in F344 rat nasal respiratory epithelium. Toxicology. 2003 May 01; 187(1):13-24.
View in: PubMed

Warabi K, Richardson MD, Barry WT, Yamaguchi K, Roush ED, Nishimura K, Kwatra MM. Human substance P receptor undergoes agonist-dependent phosphorylation by G protein-coupled receptor kinase 5 in vitro. FEBS Lett. 2002 Jun 19; 521(1-3):140-4.
View in: PubMed

Barry WT, Boudignon-Proudhon C, Shock DD, McFadden A, Weiss JM, Sondek J, Parise LV. Molecular basis of CIB binding to the integrin alpha IIb cytoplasmic domain. J Biol Chem. 2002 Aug 09; 277(32):28877-83.
View in: PubMed

DiBianco R, Schoomaker FW, Singh JB, Awan NA, Bennett T, Canosa FL, Kawanishi DT, Bamrah VS, Glasser SP, Barry W. Amlodipine combined with beta blockade for chronic angina: results of a multicenter, placebo-controlled, randomized double-blind study. Clin Cardiol. 1992 Jul; 15(7):519-24.
View in: PubMed

Top